Coda Octopus Group (CODA) Q2 2025 Earnings Call June 16, 2025 10:00 AM ET Company Participants Geoff Turner - Investor RelationsAnnmarie Gayle - Chairman & CEOBlair Cunningham - President - Technology & Divisional CEO of Coda Octopus Products IncGayle Jardine - Interim CFOBrian Kinstlinger - MD, Director of Research & Head of Technology ResearchJohn Deysher - Portifolio Manager Operator Good morning, and welcome to Coda Octopus Group's Second Quarter Fiscal twenty twenty five Earnings Conference Call. My na ...

Financial Data and Key Metrics Changes - In Q2 2025, total revenue increased by 31.8% to $7 million from $5.3 million in Q2 2024 [36] - Operating income decreased by 19.5% to $1.1 million compared to $1.4 million in Q2 2024 [40] - Gross profit increased to $4.5 million, but gross margin decreased to 64.1% from 70.2% in the prior year [37][41] - Net income after tax was $900,000 or $0.08 per diluted share, down from $1.4 million or $0.13 per diluted share in Q2 2024 [41] Business Line Data and Key Metrics Changes - The marine technology business generated $3.9 million in revenue, a 10% increase from $3.5 million in Q2 2024 [36] - The marine engineering business saw a revenue increase of 2.3% to $1.84 million [36] - The newly acquired Precision Acoustics Limited contributed 18.5% to consolidated revenue and 13.4% to operating income [17][36] Market Data and Key Metrics Changes - Hardware sales to Asia rose by approximately 105%, reaching $2.2 million compared to $1.1 million in Q2 2024 [14] - The marine technology business accounted for 55.3% of total consolidated revenue in Q2 2025 [6] Company Strategy and Development Direction - The company is focusing on increasing market share in underwater imaging sensors, particularly in the defense sector [9] - The launch of the NanoGen series is aimed at addressing smaller underwater vehicles and enhancing market opportunities [11][24] - The company is pursuing a multi-year, multi-sales model for its marine technology business [47] Management's Comments on Operating Environment and Future Outlook - Management noted a challenging global policy environment but expressed optimism about increasing inquiries and rental utilization [5][15] - The company is focused on executing its growth strategy and adapting to changes in the defense market [46] Other Important Information - The company is under contract for five development programs related to the DAVID system, which integrates with existing diving equipment [55][58] - The company has paused its M&A strategy until the global policy environment stabilizes [47] Q&A Session Summary Question: What led to the stronger than expected second quarter demand from Marine Products? - Management noted strong inquiries around Echoscope technology, particularly from Asia, and a pickup in DAVID program sales [50] Question: What is the expected timing for the new NanoGen release? - The NanoGen series is on the cusp of release, with trials expected to conclude by the end of June [52] Question: Can you provide a range of sizes for the development programs? - The five programs primarily focus on integrating the DAVID system with existing underwater breathing apparatus equipment [55] Question: What progress is CODA making in securing design wins for next-generation underwater vehicles? - Management indicated ongoing evaluations and integration of Echoscope technology into various defense programs [60] Question: Should gross margin percentages be modeled for the back half of the year? - Management expects gross margins to improve in the second half of the year, returning to typical levels [70] Question: What revenue contribution might the delivery of 16 DAVID untethered systems generate? - The expected revenue from delivering 16 units is around $800,000 [78]

Nano-X Imaging (NNOX) Conference June 11, 2025 01:45 PM ET Speaker0 Welcome to submit questions using the Zoom Q and A interface at the bottom of your screen. After the presentation, we'll open to your questions. And with that, Ron, I'll turn it over to you. Speaker1 You, Alex, and good afternoon for everyone. Before we'll get started, I would like to remind everyone that I'll be making statements during this presentation that may be deemed forward looking statements regarding our activities, commercializat ...

MELBOURNE, Australia and INDIANAPOLIS, June 11, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that its next-generation PSMA-PET imaging1 agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), is now commercially available nationally in the United States (U.S.). Gozellix is available through Telix’s comprehensive network of distribution partners, Cardinal Health, Inc., PharmaLogic Holdi ...

Lantheus (LNTH) FY Conference June 10, 2025 02:40 PM ET Speaker0 Following session is not open to the press. Okay. Speaker1 Good afternoon, everyone. I'm Paul Choi, and I cover the biotechnology sector here at the firm at Goldman Sachs. It's my pleasure to welcome Lampius. Joining me on stage to my immediate left is Brian Markinson, CEO, and Bob Marshall to my far left. What I'll do is turn it over to Brian maybe for some introductory or overview comments and then we'll get into Q and A after that. Speaker0 ...

Summary of Nano-X Imaging (NNOX) Conference Call Company Overview - **Company**: Nano-X Imaging Limited - **Industry**: Medical Imaging Technology - **Key Product**: Nanox ARC, a proprietary imaging device that combines advanced imaging technology with a cloud-based platform for enhanced medical diagnostics [4][6][13] Core Points and Arguments - **Technological Advancements**: The company is focused on improving medical imaging and patient outcomes through innovative technologies, including the Nanox ARC and AI solutions [4][21] - **Regulatory Approvals**: Achieved FDA clearance for musculoskeletal (MSK) imaging in May 2023 and CE marking for all body imaging in February 2025, indicating significant progress in regulatory compliance [21][23] - **Market Strategy**: Targeting the U.S. market with a focus on imaging centers, multi-specialty medical centers, and urgent care facilities. The company employs a direct sales team and partners with distributors for broader reach [23][24] - **Business Model**: Offers a pay-per-use model charging $30 per scan, requiring a minimum of seven scans per day under a multi-year agreement. This model is designed to minimize capital expenditure for operators [27][28] - **Financial Position**: As of March 31, 2025, the company reported $73 million in cash and cash equivalents, with a quarterly run rate of $3 million [50] Additional Important Content - **Product Features**: The Nanox ARC system is designed to be smaller, lighter, and simpler than traditional X-ray systems, providing 3D tomosynthesis images with reduced radiation exposure compared to CT scans [12][18] - **Clinical Benefits**: The technology allows for better visualization and reduced false positives, expediting diagnosis while maintaining lower costs compared to CT imaging [17][19] - **Future Developments**: The company is working on an upgraded version of the Nanox ARC with a smaller footprint and enhanced capabilities, which will allow for more installations in space-constrained environments [31][32] - **AI Solutions**: The company has developed AI solutions for various medical applications, including vertebral compression fractures and coronary artery calcium measurement, with plans for future applications in orthopedics and body composition [45][46] - **Global Presence**: The company has installations in the U.S., Israel, and Ghana, with ongoing clinical trials and partnerships to expand its market presence [30][49] Conclusion Nano-X Imaging Limited is positioned to disrupt the medical imaging industry with its innovative technology and business model, backed by regulatory approvals and a clear market strategy. The focus on cost-effective solutions and advanced imaging capabilities presents significant growth potential in the healthcare sector [4][21][23][27]

Key Takeaways Hyperfine received FDA clearance for its next-generation Swoop Portable MR Imaging system. HYPR's new Swoop system uses OptiVu AI to enhance image resolution, speed, and diagnostic utility. Hyperfine aims to expand clinical use with a compact, mobile design suited for diverse care settings.Hyperfine (HYPR) recently announced FDA 510(k) clearance for its next-generation Swoop Portable MR Imaging system. The clearance covers an entirely new portable magnetic resonance imaging (MRI) scanner pow ...

Company Overview - Coda Octopus Group, Inc. is a global leader in real-time 3D/4D/5D and 6D imaging sonar technology for subsea intelligence and augmented reality diving technology [4] - The company was founded in 1994 and provides hardware and software solutions for the underwater/subsea market, including proprietary imaging sonars and diving technology [4] Upcoming Conference Call - The company will host a conference call on June 16, 2025, at 10:00 a.m. Eastern time to discuss its fiscal second quarter results for the period ending April 30, 2025 [1][2] - A press release detailing the results will be issued before the market opens on the same day [2] Technology and Products - Coda Octopus's Echoscope technology generates real-time 3D/4D/5D images of underwater objects, even in zero visibility conditions, and is used in various applications including mapping, salvage, and offshore renewables [4] - The newly launched Diver Augmented Vision Display (DAVD) system integrates sonar technology and allows for improved communication and visualization between topside control and divers [5] Recent Acquisition - The company recently acquired Precision Acoustics Limited, enhancing its capabilities in acoustics sensor and materials [6] Defense Engineering Businesses - Coda Octopus operates two defense engineering businesses, Coda Octopus Martech Ltd and Coda Octopus Colmek, which supply sub-assemblies for mission-critical programs as subcontractors [7]

Core Insights - Spectral AI's DeepView System has demonstrated a 95.3% overall accuracy in predicting burn healing potential, significantly outperforming traditional subjective assessments [1][2] - The technology has been recognized in the journal Burns, highlighting its clinical importance and transformative role in burn care [2] Company Overview - Spectral AI, Inc. is a Dallas-based predictive AI company focused on enhancing medical diagnostics for wound care, particularly for burn patients [3] - The DeepView System aims to provide objective and immediate assessments of burn wounds, facilitating faster and more accurate treatment decisions [3] - The company is committed to improving patient outcomes and reducing healthcare costs through its innovative technology [3] Clinical Significance - The study published in Burns represents the first multi-center evaluation of AI-enhanced multispectral imaging in burn assessment, showcasing the effectiveness of the DeepView System across various clinical settings [2] - The technology empowers clinicians with data-driven insights, improving decision-making regarding healing time and the need for surgical interventions [2] Industry Context - Burns is a prominent peer-reviewed medical journal dedicated to advancements in burn care and wound healing, serving as a critical platform for sharing innovative techniques and best practices [2]

今天分享的是：中国高端手机影像趋势与用户洞察-知乎研究院 报告共计：5页 《中国高端手机影像趋势与用户洞察-知乎研究院》显示，手机已成为影像爱好者的核心设备，77.2%用户以手机为主力拍摄工具，71.8%每日用手机记录生 活，27%会分享至社媒。用户摄影水平提升，61.3%常切换拍摄模式和参数，专业影像组更注重分享与创作，手机影像组则侧重个人记录。拍摄题材以风 光、人文、人像为主，手机用户常用24-26mm默认焦段，专业用户更偏好35mm焦段。后期处理中，50%用户在手机完成修图，但专业用户耗时更久，53% 对手机后期功能有更高期待。 用户认为手机影像在对焦速度、场景感光、运动抓拍等方面存在不足，43.1%认可高端影像手机可部分替代专业设备，但专业用户认为手机操作复杂。选购 高端手机时，影像能力是基础门槛，用户关注硬件配置（如潜望式长焦、多光谱传感器）、AI功能（自动修图、创意创作）及便携性，40%愿将高端影像手 机作为副机。 未来趋势上，AI深度融入影像全流程，用户期待AI在画质提升、拍摄辅助等方面突破，64.2%期望3D/AR影像交互，46.8%关注可变光圈。超半数用户认为 顶级影像赛事接纳手机作品将是行 ...